EP1263472A2 - Modification of biopolymers for improved drug delivery - Google Patents
Modification of biopolymers for improved drug deliveryInfo
- Publication number
- EP1263472A2 EP1263472A2 EP01910775A EP01910775A EP1263472A2 EP 1263472 A2 EP1263472 A2 EP 1263472A2 EP 01910775 A EP01910775 A EP 01910775A EP 01910775 A EP01910775 A EP 01910775A EP 1263472 A2 EP1263472 A2 EP 1263472A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- biopolymer
- group
- conjugate
- therapeutic agent
- chemically modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Definitions
- This application claims priority to U.S. Provisional Application No. 60/182,558 filed February 15, 2000 and to U.S. Provisional Application No. 60/211,508 filed June 14, 2000.
- This invention relates to the chemical modification of biopolymers for the delivery of therapeutic agents, such as therapeutic proteins, to specific tissues, organs or cells within a subject, or to extend the bioavailability of the therapeutic agent by enhancing its in vivo stability.
- the biopolymer is initially modified to introduce one or more disulfide bonds into a side chain of the biopolymer. This facilitates the reaction of the biopolymer with a therapeutic agent that has also been modified to present a reactive thiol moiety to form the biopolymer-therapeutic agent conjugate.
- the site-specific reaction of the biopolymer and the therapeutic agent increases the stability of the therapeutic agent upon delivery to the desired site targeted by the biopolymer.
- Biopolymers are biocompatible polymers that are useful for a wide variety of biomedical applications, such as for surgical aids, to prevent or reduce the formation of surgical adhesions, and for drug delivery applications. Many biopolymers are naturally occurring substances found in the body, and therefore do not have any unacceptable toxic or injurious effects on biological function.
- An example of such a biopolymer is hyaluronic acid ("HA"), a naturally occurring mucopolysaccharide found, for example, in synovial fluid, in vitreous humor, in blood vessel walls and the umbilical cord, and in other connective tissues.
- HA hyaluronic acid
- Hyaluronic acid consists of alternating N-acetyl-D-glucosamine and D-glucuronic acid residues joined by alternating ⁇ 1-3 glucuronidic and ⁇ 1-4 glucosaminidic bonds, so that the repeating unit is -(l ⁇ 4)- ⁇ -D-GlcA-(l ⁇ 3)- ⁇ -D- Glc ⁇ Ac-.
- hyaluronic acid dissolves to form a highly viscous fluid.
- the molecular weight of hyaluronic acid isolated from natural sources generally falls within the range of 5 x 10 4 up to 1 x 10 7 daltons.
- U.S. Pat. No. 4,582,865 to Balazs et al. states, inter alia, that cross-linked gels of
- HA can slow the release of a low molecular weight substance that is dispersed therein but not covalently attached to the gel macromolecular matrix.
- U.S. Patent No. 4,636,524 which contains a disclosure of related technology. Both of these patents describe HA compositions in which the HA is crosslinked by reaction with divinyl sulfone, and the use of the crosslinked HA compositions in drug delivery applications.
- compositions for the in vivo delivery of insoluble pharmaceutically active agents Delivery of the drug substances is achieved, for instance, by encasing the active agent in a polymeric shell formed from a biocompatible polymer.
- the biocompatible polymer may be protein, lipid, DNA molecule or polysacharide, and the pharmaceutically active agent may be a therapeutic protein such as taxol.
- the polymer contains covalently attached sulfhydryl groups or disulfide linkages which can be crosslinked to form disulfide bonds.
- the polymeric shell is formed using ultrasonic irradiation techniques.
- U.S. Patent No. 5,496,872 relates to biocompatible and biodegradable crosslinkable polymers having reactive thiol groups.
- the reactive thiol groups can be crosslinked to form disulfide linkages between adjacent molecules, resulting in a three dimensional network.
- These polymers can be used for binding tissues or binding tissues with implanted biomaterials.
- U.S. Patent No. 5,932,552 describes a keratin hydrogel having biomedical applications.
- the hydrogel is formed from crosslinked keratin bound by disulfide linkages.
- biomedical applications described in the patent are uses of the hydrogels for cell scaffolding in tissue repair.
- U.S. Patent Nos. 5,354,853 and 5,451 ,661 describe, respectively, the preparation of phospholipid-saccharide conjugates, and lipids conjugated to biologically active agents such as peptides, proteins and nucleic acids. These conjugates are described as being particularly useful in drug delivery applications.
- U.S. Patent No. 5,902,795 to Toole et al., discloses hyaluronic acid oligosaccharides, having between one and sixteen repeating units, which are used to treat tumors in mammals.
- the patent states that the oligosaccharides act to reduce the level of membrane-associated hyaluronan-binding proteins, which are expressed on the surface of certain tumor cells during cell migration. The treatment is believed to reduce the incidence of tumor metastasis in the mammals.
- CMC carboxymethyl cellulose
- polycarbophil modified with L- cysteine using carbodiimide chemistry.
- the polymers are reacted with the cysteine to form an amide bond between the primary amino group of the amino acid and the carboxylic acid of the polymer.
- the thiolated polymers were allowed to oxidize to form disulfide bridges. The dissolution of these tablets, both with and without drugs, was analyzed. The tablets were found to have improved stability and viscoelasticity.
- Copending U.S. Patent Application Serial No. 09/430,857 relates to surfaces that have been modified by the attachment of hyaluronic acid.
- the surface can be part of a medical device, such as a stent or a surgical tubing.
- the surface is modified to include a reactive amino group that reacts with a derivatized hyaluronic acid.
- the modified devices and instruments are hydrophilic, and have anti-fouling and anti-platelet adhesion characteristics, thereby producing a reduction in risks associated with thrombosis.
- the conjugated biopolymers of this invention represent a significant improvement over drug delivery vehicles of the prior art due, in part, to the site-specific reaction between the biopolymer and the therapeutic agent which increases the stability and activity of the therapeutic agent upon delivery to the desired site within a subject.
- the present invention features a biopolymer-therapeutic agent conjugate in which the biopolymer and therapeutic agent are joined by a disulfide bond.
- the biologically active conjugate of this invention is useful as a drug delivery vehicle for the in vivo delivery of the therapeutic proteins to specific cells, organs or tissues in a subject. Drug delivery specificity is achieved by appropriate selection of the structure and molecular weight of the biopolymer.
- the chemistry used to prepare the conjugates permits the site-specific reaction between the biopolymer and the therapeutic agent.
- the therapeutic agent contains a reactive thiol group, which can be present in an unmodified version of the therapeutic agent, as in the case of cysteine for example.
- the thiol group can be introduced into a modified version of a therapeutic agent that does not normally contain a reactive thiol group.
- the therapeutic agent can be reacted, through the reactive thiol group, with a chemically modified version of the biopolymer. This reaction typically occurs at a pH in the range of from about 6.0 to about 10.
- the biopolymer is activated and modified by reaction with an activating agent, such as a carbodiimide, and reacted with an organic disulfide compound.
- the organic disulfide compound contains a terminal group, such as an amino group or a hydroxyl group, which is reactive with the carboxylic acid group of the biopolymer in the presence of the activating agent.
- the reaction of the biopolymer, activating agent and organic disulfide compound occurs at a pH of from about 2.0 to 8.0.
- the therapeutic agent can be reacted, again through the thiol group, with the reducing end of the biopolymer.
- the biopolymer is first reacted with an organic disulfide compound containing a terminal group, such as an amino group or a hydroxyl group, which is reactive with the terminal carboxyl group of the biopolymer.
- the reaction of the biopolymer and organic disulfide compound occurs over a wide pH range, typically at a pH of from about 2.0 to 9.0.
- the reaction of the biopolymer and therapeutic agent results in the attachment of the biopolymer to the therapeutic agent through a disulfide bond.
- the linking group or spacer which can be a lower alkyl, separates the biopolymer from the therapeutic agent.
- the linking or spacer is a residue resulting from the cleavage of the organic disulfide compound by the reactive thiol of the therapeutic agent.
- Typical biopolymers include any of the polyanionic polysaccharides, such as hyaluronic acid and any of its hyaluronate salts, such as sodium hyaluronate, potassium hyaluronate, magnesium hyaluronate and calcium hyaluronate, carboxymethyl cellulose, carboxymethyl amylose, chondroitin-6-sulfate, dermatin sulfate, heparin, and heparin sulfate, as well as polyacrylic acid, polycarbophil, carboxymethyl chitosan, poly- ⁇ - glutamic acid, poly- ⁇ -glutamic acid, carrageenan, and sodium alginate.
- polyanionic polysaccharides such as hyaluronic acid and any of its hyaluronate salts, such as sodium hyaluronate, potassium hyaluronate, magnesium hyaluronate and calcium hyaluronate
- biopolymers of this invention are biocompatible, as that term is defined herein, they contain carboxylic acid functionality, and they can be modified to react with an organic disulfide compound.
- modification can occur, for instance, by reaction of the biopolymer with a suitable activating agent, such as a carbodiimide, to render the carboxylic group vulnerable to nucleophilic attack by, for instance, an amine or a hydroxyl.
- a suitable activating agent such as a carbodiimide
- the modification can occur at the terminal or end group of the biopolymer by reduction of a terminal carbonyl group using a Schiff base.
- the biopolymer is hyaluronic acid having a molecular weight in the range of from about 7.5 x 10 2 daltons to about lx 10 7 daltons.
- the hyaluronic acid is preferably activated by reaction with an activating agent to render it vulnerable to nucleophilic attack.
- Suitable activating agents for this purpose include carbodiimides, such as l-ethyl-3-(3-dimethylaminopropyl) carbodiimide and l-ethyl-3- (3-dimethylaminopropyl) carbodiimide methiodide.
- the organic disulfide compound can be virtually any organic compound having a disulfide bond.
- the disulfide bond is positioned at one end of an alkyl chain, while the other end of the chain terminates in a group reactive with the carbonyl group of the biopolymer.
- the group that reacts with the biopolymer is an amino, carboxyl or hydroxyl group, but most preferably an amino group.
- the organic disulfide compound is also capable of reacting with the active thiol group of the therapeutic agent.
- Preferred organic disulfide compounds include, in general, the nitro-pyridines, thio-pyridines, substituted S-phenyl disulphides, S-sulfonate derivatives, 9-anthrymethyl thioesters, S- carboxymethyl derivatives and nitro-thiobenzoic acid derivatives. More preferably, the organic disulfide compound is a thio-nitro-pyridine, and most preferably 3-nitro-2- pyridinesulfeny 1-ethylamine .
- the therapeutic agent is preferably one or more of the following: small organic molecules, proteins, nucleic acids, antibodies, peptides, amino acids, lipids, polysaccharides, cell growth factors, and enzymes.
- the therapeutic agent is native or recombinant colony-stimulating factor ("CSF"), an amino acid or glucocerebrosidase.
- CSF colony-stimulating factor
- the therapeutic agent should contain a reactive thiol group to react with the modified biopolymer.
- the reactive thiol group can either be inherently part of the therapeutic agent, as in the case of cysteine, or the reactive thiol group can be introduced into the therapeutic molecule using known techniques.
- a free thiol group can be introduced into a recombinant therapeutic protein molecule for conjugation and modification.
- some therapeutic drugs such as Captopril - a drug used to treat hypertension - inherently contain a free sulfhydryl group as shown in the structure below:
- amino groups of therapeutic agents can be conveniently converted into thiols by reaction with Traut's Reagent (aminothiolane).
- the therapeutic agent is selected for the particular indication that is to be treated, and the biopolymer is selected, both as to its type and molecular weight, for its ability to target a particular organ, cell or tissue.
- a therapeutic agent for treating Gaucher's Disease, a serious liver ailment is the enzyme glucocerebrosidase.
- Glucocerebrosidase can be targeted to the liver by forming a conjugate with an appropriately sized hyaluronic acid molecule.
- the biologically active conjugate of the present invention provides for improved stability of the therapeutic agent as compared to the use of the unconjugated or unmodified therapeutic agent, or the use of other carriers or conjugated compounds, such as polyethylene glycol (“PEG”) or lipids.
- PEG polyethylene glycol
- the improved stability results in increased residence time in the body of a subject and increased circulation time in the blood stream.
- the conjugates of this invention also display improved targeting to specific tissues, organs and cells. Improved targeting is achieved through the selection of specific types and molecular weights of the biopolymers.
- the invention involves the attachment of a biopolymer onto the surface of a substrate by means of a disulfide linkage.
- the substrate can be a polymeric material, a ceramic or a metal.
- the substrate is part of a medical device or instrument, such as a stent, graft, suture, catheter, tubing or guidewire.
- the substrate is modified to contain an amino group, which can then be converted into a thiol group.
- the substrate can then be reacted with the biopolymer modified with the organic disulfide compound to immobilize the biopolymer onto the substrate.
- Fig. 1 is a graph illustrating the UV analysis of hyaluronic acid modified with 3- nitro-2-pyridinesulfenyl-ethylamine.
- Fig. 2 is an H 1 NMR trace of hyaluronic acid modified with 3-nitro-2- pyridinesulfenyl-ethylamine.
- Fig. 3 is a trace of an IR spectra of hyaluronic acid modified with 3-nitro-2- pyridinesulfenyl-ethylamine.
- the biologically active biopolymer-therapeutic agent conjugates of the present invention can be prepared by using a variety of chemical preparatory methods.
- An important feature of the conjugates of this invention is that the linkage between the therapeutic agent and biopolymer contains a disulfide bond.
- the disulfide bond is formed by the reaction of the therapeutic agent containing an active thiol with the biopolymer, which has also been modified to contain a disulfide group by reaction with an organic disulfide compound.
- the procedure for preparing the biopolymer-therapeutic agent conjugates of this invention is described in more detail below. Prior to the preparation of the conjugate, it is necessary to first select an appropriate biopolymer.
- biopolymer is selected from biocompatible polymers that contain a carbonyl group.
- biocompatible is intended to denote a substance that has no medically unacceptable toxic or injurious effects on biological function, or which is tolerated by the body.
- biopolymers examples include the polyanionic polysaccharides, such as hyaluronic acid and any of its hyaluronate salts, such as sodium hyaluronate, potassium hyaluronate, magnesium hyaluronate and calcium hyaluronate, carboxymethyl cellulose ("CMC"), carboxymethyl amylose, carboxymethyl chitosan, chondroitin-6-sulfate, dermatin sulfate, heparin, and heparin sulfate, as well as poly- ⁇ -glutamic acid, poly- ⁇ -glutamic acid, carrageenan, and sodium alginate.
- polyanionic polysaccharide is intended to mean polysaccharides containing more than one negatively charged group, e.g. carboxyl groups at pH values above about a pH of 4.0.
- Biopolymers suitable for a particular application are selected from this group of candidate biopolymers on the basis of their ability to target particular tissues, organs or cells, and their in vivo stability, i.e. the in vivo residence time in the circulatory system, or specific tissues, cells or organs.
- the biopolymer is hyaluronic acid having a molecular weight in the range of from about 7.5 x 10 2 daltons to about 1 x 10 7 daltons.
- These biopolymers can be "activated” by reacting the biopolymer with a suitable activating agent to render the carboxylic group on the biopolymer vulnerable to nucleophilic attack.
- Suitable activating agents include carbodiimides, and preferably 1- ethyl-3-(3-dimethylaminopropyl) carbodiimide and l-ethyl-3-(3-dimethylaminopropyl) carbodiimide methiodide.
- the reaction between the biopolymer and activating agent occurs in an aqueous medium, preferably at a pH of from about 2.0 to about 8.0, and more preferably a pH of from about 4.0 to about 5.1.
- Activation of the biopolymer can be useful if the therapeutic agent is linked to the intermediate carboxylic acid groups of the biopolymer.
- organic disulfide compounds can be selected from a wide range of molecules, including the nitro-pyridines, thio-pyridines, substituted S-phenyl disulfides, S-sulfonate derivatives, 9-anthrymethyl thioesters, S-carboxymethyl derivatives and nitro- thiobenzoic acid derivatives, and preferably the thio-nitro-pyridines.
- a particularly preferred organic disulfide compound is 3-nitro-2-pyridinesulfenyl-ethylamine.
- the organic disulfide compound is a compound of general formula
- R is an amino, hydroxyl or carbonyl group
- L if present, is a spacer, preferably a lower normal or iso-substituted alkyl group, and more preferably an ethyl group, each S is a sulfur atom, and M is an organic moiety.
- the spacer, L contains a terminal group that is reactive with the activated biopolymer.
- the terminal group is an amino, carboxyl or hydroxyl group, but most preferably an amino group.
- the organic disulfide compound is also capable of reacting with the active thiol group of the therapeutic agent.
- benzyl-3-nitro-2-pyridyl-sulfide is reacted with dichloroethane and sulfuryl chloride to prepare 3-nitro-2-pyridinesulfenyl chloride.
- the 3-nitro-2- pyridinesulfenyl chloride is reacted with 2-aminoethanethiol and formic acid to prepare 3-nitro-2-pyridinesulfenyl-ethylamine as a precipitated product.
- the activated biopolymer can then be reacted with the organic disulfide compound as shown in the following reaction scheme:
- G is a biopolymer with a pendant carboxyl group
- R is preferably an amino group
- L if present, is a spacer, preferably a lower alkyl group
- each S is a sulfur atom
- M is an organic moiety.
- the organic disulfide compound is 3-nitro-2- pyridinesulfenyl-ethylamine ("NEA”), and the reaction of NEA and hyaluronic acid, the preferred biopolymer, can be illustrated as shown below, where "EDC” designates 1- ethyl-3-(3-dimethylaminopropyl) carbodiimide, and "HOBt” designates hydroxybenzotriazole :
- the biopolymer can be reacted with the organic disulfide compound as shown in the following reaction scheme:
- the organic disulfide compound is 3-nitro-2-pyridinesulfenyl-ethylamine ("NEA"), and the reaction of NEA and hyaluronic acid, the preferred biopolymer, can be illustrated as shown below, where NaCNBH 3 is sodium cyanoborohydride:
- the biopolymer terminal ring opens as a result of a mutarotation equilibrium which occurs naturally in carbohydrates. This forms a terminal aldehyde group, which is the only aldehyde group in the molecule and can form a Schiff base.
- the aldehyde reacts with the terminal amino group of the organic disulfide compound.
- the addition of the sodium cyanoborohydride is a well known reaction to reduce the resulting Schiff base.
- reagents which are known to be able to reduce Schiff bases include sodium borohydride, lithium borohydride, lithium cyanoborohydride, sodium aluminum hydride, lithium aluminum hydride, tetrabutyl ammonium cyanobororhydride, sodium amalgam, potassium graphite, and catalytic hydrogenation over platinum or nickel.
- this embodiment results in the attachment of the organic disulfide compound to the reducing end of the biopolymer. This permits the reaction of one mole of organic disulfide compound per mole of biopolymer in a quantitatively controlled manner, which can be result in higher yields, and more precise drug targeting and delivery.
- the attachment of the organic disulfide compound need not be restricted to aldehydes inherent in the biopolymer.
- the organic disulfide compound may be reacted with the biopolymer as described herein.
- the biopolymer-organic disulfide complex is then reacted with a therapeutic agent of choice.
- the therapeutic agent is selected based on the particular disease state to be treated, and the organ, tissue or cell to be targeted. Suitable therapeutic agents include small organic molecules, proteins, nucleic acids, antibodies, peptides, amino acids, lipids, polysaccharides, cell growth factors, and enzymes. More preferably, the therapeutic agent is native or recombinant colony stimulating factor, an amino acid or glucocerebrosidase.
- Glucocerebrosidase is an enzyme which is used to treat a liver condition known as Gaucher's Disease.
- glucocerebrosidase is selected as the therapeutic agent, it is advantageous to also select hyaluronic acid, having an appropriate molecular weight, to target the therapeutic agent to liver cells.
- hyaluronic acid having an appropriate molecular weight
- the therapeutic agent of choice contains an active thiol (-SH) group, that reacts with the HA-NEA conjugate, displacing the thio- nitro-pyridine residue.
- the therapeutic agent (shown above as the solid circle) is attached to the hyaluronic acid by a disulfide bond and an amine-terminated ethyl chain (spacer). The reaction occurs at a neutral to basic pH in the range of from about 6 - 10.
- the biologically active conjugates of this invention can be formulated as pharmaceutical compositions for medical diagnosis or treatment, together with appropriate pharmaceutically acceptable carriers and, optionally, other therapeutic or diagnostic agents, using well known formulation protocols.
- Administration of the pharmaceutical composition can be accomplished using an appropriate vehicle, such as tablets, implants, injectable solutions, and the like.
- Acceptable carriers include buffering agents and adjuvants.
- the precise amount of the biologically active conjugate used in the pharmaceutical composition can be determined based on the nature of the condition to be treated, and the potency of the therapeutic agent used. This invention contemplates both local administration and time release modes of administration.
- the term "subject” is intended to denote a human or non-human mammal, including, but not limited to, a dog, cat, horse, cow, pig, sheep, goat, chicken, primate, rat and mouse.
- the process of the present invention can also be employed to modify the surface of a medical device or instrument.
- a biopolymer such as hyaluronic acid, can be immobilized onto the surface of a substrate which has been modified to contain, for instance, exposed amino groups, which can be reacted with Traut's reagent and then HA- NEA as shown below:
- the aminated surface prepared, for instance, by cold plasma deposition of an allyl amine, is treated with a reagent, such as Traut's reagent, to convert the amino groups into free thiol groups.
- a reagent such as Traut's reagent
- the derivatized surface is then reacted with HA-NEA to immobilize HA to the surface by a disulfide bond.
- the advantage of this approach is the specificity of the reaction for the free sulfhydryl group between the surface and the activated disulfide in the biopolymer. Under these reaction conditions, the activated biopolymer can only react with the surface and not with other biopolymer molecules, thereby creating a modified surface having a well defined biopolymer thickness.
- exogenously added activating agents such as glutaraldehyde and carbodiimide
- glutaraldehyde and carbodiimide can result in interpolymer covalent bond formation that can cause uncontrolled increases in biopolymer coating thicknesses.
- Another advantage is the use of mild reaction conditions, such as the use of an aqueous solvent, ambient temperatures, and a pH in the range of from about 6-10.
- This surface modification approach can be used to modify the surface characteristics of stents, to prevent platelet activation and aggregation, or catheter surfaces, to inhibit cell adhesion.
- An additional advantage of this approach is that the
- HA will only react with the surface, and not with itself, so the thickness and composition of the HA layer can be readily controlled.
- Benzyl-3-nitro-2-pyridyl sulfide (10 grams, 40.6 mmol.), that had been azeotropically dried by coevaporation with toluene, was dissolved in 1,1-dichloroethane (21 mL). The reaction solution was cooled to 0° C, and sulfuryl chloride (4.24 mL, 52.78 mmol) was added, followed by triethylamine (100 ⁇ L. 1.4 mmol). This resulted in a precipitate that was collected, washed with hexane, dried under reduced pressure, and was used without further purification.
- HOBt (16.8 mg, 124 ⁇ mol) was added to an 8.0% solution (312 ⁇ L, 62 ⁇ mol) of 70 kdalton HA, followed by the addition of NEA (25.0 mg, 93 ⁇ mol).
- the pH of the reaction mixture was adjusted to 3.0 by the addition of 2M HCl.
- EDC 178.3 mg, 930.1 ⁇ mol was added to the acidified reaction mixture, and the mixture was stirred at room temperature for 1.5 hours. All of the above reagents were dissolved in sufficient water to achieve a final HA concentration in the reaction solution of 1%.
- the reaction was purified by dialysis against phosphate buffered saline ("PBS”) for 24 hours, followed by dialysis against water for an additional 24 hours. The product was recovered by lyophilization.
- PBS phosphate buffered saline
- NMP N-methylpyrrolidone
- HOBt (16.8 mg, 124 ⁇ mol) was added to an 8.0% solution (312 ⁇ L, 62 ⁇ mol) of 70 kdalton HA, followed by the addition of NEA (25.0 mg, 93 ⁇ mol).
- the pH of the reaction mixture was adjusted to 3.0 by the addition of 2M HCl.
- EDC (35.7 mg, 186 ⁇ mol) was added to the acidified reaction mixture, and the mixture was stirred at room temperature for 1.5 hours. All of the above reagents were dissolved in a sufficient amount of a 50:50 NMP/water mixture to achieve a final HA concentration in the reaction solution of 1%.
- the reaction was purified by dialysis against phosphate buffered saline ("PBS”) for 24 hours, followed by dialysis against water for an additional 24 hours. The product was recovered by lyophilization.
- PBS phosphate buffered saline
- HOBt (16.8 mg, 124 ⁇ mol) was added to an 8.0% solution (312 ⁇ L, 62 ⁇ mol) of 70 kdalton HA, followed by the addition of NEA (25.0 mg, 93 ⁇ mol).
- the pH of the reaction mixture was adjusted to 3.0 by the addition of 2M HCl.
- EDC (35.7 mg, 186 ⁇ mol) was added to the acidified reaction mixture, and the mixture was stirred at room temperature for 1.5 hours. All of the above reagents were dissolved in a sufficient amount of a 50:50 EtOH/water mixture to achieve a final HA concentration in the reaction solution of 1%.
- the reaction was purified by dialysis against phosphate buffered saline ("PBS”) for 24 hours, followed by dialysis against water for an additional 24 hours. The product was recovered by lyophilization.
- PBS phosphate buffered saline
- HOBt (33.5mg, 248 ⁇ mol) was added to a 1.0% solution (5 mL,124 ⁇ mol) of 100 kdalton HA, followed by the addition of 50.0 mg (186 ⁇ mol) of NEA.
- the pH of the reaction mixture was adjusted to 3.0 by the addition of 2M HCl.
- EDC 142.7 mg, 744 ⁇ mol was added to the acidified reaction mixture, and the mixture was stirred at room temperature for 1.5 hours. All of the above reagents were dissolved in sufficient water to achieve a final HA concentration in the reaction solution of 0.2%.
- the reaction was purified by dialysis against phosphate buffered saline ("PBS”) for 12 hours, followed by dialysis against water for an additional 12 hours. The product was recovered by lyophilization.
- PBS phosphate buffered saline
- UV analysis of the HA-NEA complex reveals a ⁇ max at 345 nm, corresponding to the 3-nitro-2-pyridinesulfenyl group which results in a bathochro ic shift to 401 nm upon reduction with DTT (Fig. 1).
- the ⁇ NMR shows a distinct set of peaks in the aromatic region generated from the 3-nitro-2- pyridinesulfenyl group (Fig. 2).
- Evidence of the modified HA structure can also be found in the IR spectra (Fig. 3). An amide stretch is observed at 1655 cm “1 , while the HA carboxyl peak at 1655 cm "1 is reduced.
- the IR spectrum contains additional peaks that can be attributed to the 3-nitro-2-pyridinesulfenyl group, specifically, the aromatic nitro and pyrindinyl stretches occurring at 1557 cm " and 746 cm “1 , respectively.
- NEA (64.5 mg, 240 ⁇ mol) was added to 10 mL of a 2.0% solution of HA (60 kdalton, pH 4.1). The reaction was stirred at room temperature for 24 hours, at which time 151 mg (2.4mmol) of sodium cyanoborohydride was added. The mixture was then stirred for one hour. The mixture was filtered through a 0.45 ⁇ m filter and purified by dialysis against 1M NaCl for 24 hours, followed by dialysis against PBS and water for an additional 48 hours. The product was recovered by lyophilization.
- NEA (64.5 mg, 240 ⁇ mol) was added to 10 mL of a 10.0% solution of HA (60 kdalton, pH 4.1). The reaction was stirred at room temperature for 24 hours, at which time 151 mg (2.4 mmol) of sodium cyanoborohydride was added. The mixture was then stirred for one hour. The mixture was filtered through a 0.45 ⁇ m filter and purified by dialysis against 1M NaCl for 24 hours, followed by dialysis against PBS and water for an additional 48 hours. The product was recovered by lyophilization.
- Dansyl-L-cysteine in the amount of 2.25 equivalents relative to the amount of 3- nitro-2-pyridinesulfenyl, was added to of an HA-NEA (4 mg, 10 ⁇ mol) complex.
- the pH was adjusted to 8.0 with 0.5 M HCl, and the reaction was stirred at room temperature for 2 hours.
- the reaction mixture was dialyzed against PBS for 12 hours, followed by dialysis against water for an additional 12 hours.
- the retentate was then lyophilized to form an HA-cysteine conjugate with the quantitative incorporation of cysteine relative to the amount of 3-nitro-2-pyridinesulfenyl modification.
- 3-nitro-2-pyridinesulfenyl was added to an HA-NEA (4 mg,10 ⁇ mol) of complex.
- the pH was adjusted to 10.0 with 0.5 M HCl, and the reaction was stirred at room temperature for 2 hours.
- the reaction mixture was dialyzed against PBS for 12 hours, followed by dialysis against D.I. water for an additional 12 hours.
- the retentate was then lyophilized to form an HA-cysteine conjugate with the quantitative incorporation of cysteine relative to the amount of 3-nitro-2-pyridinesulfenyl modification.
- Dansyl-L-cysteine in the amount of 2.25 equivalents, relative to the amount of 3-nitro-2-pyridinesulfenyl, was added to an HA-NEA (4 mg, 10 ⁇ mol) complex.
- the pH was adjusted to 10.0 with 0.5 M HCl, and the reaction was stirred at room temperature for 2 hours.
- the reaction mixture was dialyzed against PBS for 12 hours, followed by dialysis against D.I. water for an additional 12 hours.
- the retentate was then lyophilized to form an HA-cysteine conjugate with the quantitative incorporation of cysteine relative to the amount of 3-nitro-2-pyridinesulfenyl modification.
Abstract
Description
Claims
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18255800P | 2000-02-15 | 2000-02-15 | |
US182558P | 2000-02-15 | ||
US21150800P | 2000-06-14 | 2000-06-14 | |
US211508P | 2000-06-14 | ||
PCT/US2001/004925 WO2001060412A2 (en) | 2000-02-15 | 2001-02-15 | Modification of biopolymers for improved drug delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1263472A2 true EP1263472A2 (en) | 2002-12-11 |
Family
ID=26878197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01910775A Ceased EP1263472A2 (en) | 2000-02-15 | 2001-02-15 | Modification of biopolymers for improved drug delivery |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1263472A2 (en) |
JP (1) | JP2003522806A (en) |
AU (1) | AU2001238346A1 (en) |
CA (1) | CA2400205A1 (en) |
IL (1) | IL151024A0 (en) |
WO (1) | WO2001060412A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
JP2004525621A (en) * | 2001-01-18 | 2004-08-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Bifunctional fusion protein having glucocerebrosidase activity |
WO2004060404A1 (en) * | 2002-12-27 | 2004-07-22 | Chugai Seiyaku Kabushiki Kaisha | Drug carrier |
US7803386B2 (en) | 2003-06-05 | 2010-09-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli |
EP1643958A4 (en) * | 2003-06-18 | 2010-09-01 | Nst Neurosurvival Technologies | Method for selective targeting of apoptotic cells and small molecule ligands used thereof |
JP2007509643A (en) * | 2003-10-10 | 2007-04-19 | ゲ・ミン・ルイ | Methods and compositions for growth of corneal endothelium and related cells on biopolymers and creation of artificial corneal grafts |
US7625736B2 (en) | 2004-06-04 | 2009-12-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for preparing immunogenic conjugates |
WO2006028110A1 (en) | 2004-09-07 | 2006-03-16 | Chugai Seiyaku Kabushiki Kaisha | Process for producing water-soluble hyaluronic acid modification |
PL1877099T3 (en) | 2005-04-06 | 2013-02-28 | Genzyme Corp | Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety |
US20080206276A1 (en) | 2005-07-08 | 2008-08-28 | Michael Otto | Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections |
SI2457919T1 (en) | 2007-01-18 | 2019-10-30 | Genzyme Corp | Oligosaccharides comprising an aminooxy group and conjugates thereof |
LT2889043T (en) | 2008-12-16 | 2019-07-10 | Genzyme Corporation | Synthetic intermediates for preparing oligosaccharide-protein conjugates |
WO2012118189A1 (en) | 2011-03-03 | 2012-09-07 | 中外製薬株式会社 | Hyaluronic acid derivative modified by amino-carbonic acid |
WO2012140650A2 (en) | 2011-04-12 | 2012-10-18 | Hepacore Ltd. | Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof |
BR112015004501B1 (en) | 2012-09-05 | 2021-04-13 | Chugai Seiyaku Kabushiki Kaisha | HYALURONIC ACID DERIVATIVE HAVING AMINO ACIDS AND STERILE GROUPS INTRODUCED IN THE SAME AND PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT |
KR102049568B1 (en) * | 2013-04-01 | 2019-11-27 | 삼성전자주식회사 | Composition for nucleic acid delivery containing hyaluronic acid |
GB201602359D0 (en) * | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
CN108440684A (en) * | 2018-03-22 | 2018-08-24 | 华侨大学 | A kind of NI-Cys-Alg self-assembled nanometers carrier and its preparation method and application |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991014696A1 (en) * | 1990-03-29 | 1991-10-03 | Gilead Sciences, Inc. | Oligonucleotide-transport agent disulfide conjugates |
US5639473A (en) * | 1993-02-22 | 1997-06-17 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of nucleic acids for in vivo delivery |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5169934A (en) | 1990-05-14 | 1992-12-08 | Anergen, Inc. | Intracellularly cleavable compounds |
US6335434B1 (en) * | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
AU665599B2 (en) | 1991-11-08 | 1996-01-11 | Hemosol Inc. | Hemoglobins as drug delivery agents |
US5902795A (en) | 1992-06-16 | 1999-05-11 | Trustees Of Tufts College | Oligosaccharides reactive with hyaluronan-binding protein and their methods of use |
US5329029A (en) | 1992-11-05 | 1994-07-12 | Wan Barbara Y | Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates |
US5354853A (en) | 1993-03-12 | 1994-10-11 | Genzyme Corporation | Phospholipid-saccharide conjugates |
ATE251913T1 (en) | 1997-05-21 | 2003-11-15 | Univ Leland Stanford Junior | COMPOSITION AND METHOD FOR DELAYING TRANSPORT THROUGH BIOLOGICAL MEMBRANES |
US5932552A (en) | 1997-11-26 | 1999-08-03 | Keraplast Technologies Ltd. | Keratin-based hydrogel for biomedical applications and method of production |
-
2001
- 2001-02-15 AU AU2001238346A patent/AU2001238346A1/en not_active Abandoned
- 2001-02-15 EP EP01910775A patent/EP1263472A2/en not_active Ceased
- 2001-02-15 IL IL15102401A patent/IL151024A0/en unknown
- 2001-02-15 WO PCT/US2001/004925 patent/WO2001060412A2/en active Application Filing
- 2001-02-15 CA CA002400205A patent/CA2400205A1/en not_active Abandoned
- 2001-02-15 JP JP2001559507A patent/JP2003522806A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991014696A1 (en) * | 1990-03-29 | 1991-10-03 | Gilead Sciences, Inc. | Oligonucleotide-transport agent disulfide conjugates |
US5639473A (en) * | 1993-02-22 | 1997-06-17 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of nucleic acids for in vivo delivery |
Non-Patent Citations (5)
Title |
---|
Li et al. (1998) Cancer Res. 58, 2404-2409. * |
Luo & Prestwich (1999) Bioconj. Chem. 10, 755-763. * |
Prestwich et al. (1998) J. Control Rel. 53, 93-103. * |
See also references of WO0160412A2 * |
Wang et al. (1998) Bioconj. Chem. 9, 749-757. * |
Also Published As
Publication number | Publication date |
---|---|
WO2001060412A2 (en) | 2001-08-23 |
WO2001060412A3 (en) | 2002-01-24 |
JP2003522806A (en) | 2003-07-29 |
CA2400205A1 (en) | 2001-08-23 |
IL151024A0 (en) | 2003-02-12 |
AU2001238346A1 (en) | 2001-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6749865B2 (en) | Modification of biopolymers for improved drug delivery | |
WO2001060412A2 (en) | Modification of biopolymers for improved drug delivery | |
US20220008612A1 (en) | Preparation and/or formulation of proteins cross-linked with polysaccharides | |
US5527893A (en) | Water insoluble derivatives of polyanionic polysaccharides | |
US6174999B1 (en) | Water insoluble derivatives of polyanionic polysaccharides | |
US6096727A (en) | Method for treating wounds using modified hyaluronic acid crosslinked with biscarbodiimide | |
US7029688B2 (en) | Methods and compositions to prevent formation of adhesions in biological tissues | |
US5017229A (en) | Water insoluble derivatives of hyaluronic acid | |
AU606230B2 (en) | Water insoluble derivatives of hyaluronic acid | |
EP0680990B1 (en) | Collagen-synthetic polymer matrices prepared using a multiple step reaction | |
US5874417A (en) | Functionalized derivatives of hyaluronic acid | |
US6235726B1 (en) | Water insoluble derivatives of polyanionic polysaccharides | |
US6030958A (en) | Water insoluble derivatives of hyaluronic acid | |
EP0640622A1 (en) | Polysaccharide derivative and drug carrier | |
US20080292664A1 (en) | Hydrogels and Hyaluronic Acid and Alpha, Beta-Polyaspartyl-Hydrazide and Their Biomedical and Pharmaceutical Uses | |
JP2003518526A (en) | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) | |
WO2001041827A1 (en) | Internally supported biomimetic materials and coatings | |
CA2140108A1 (en) | Collagen-synthetic polymer conjugates having controlled fiber size distributions | |
JP2019528837A (en) | Combination with albumin, especially for cartilage defect treatment | |
JPH09124512A (en) | Water-soluble medicine-pullulan combination preparation for targeting liver |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020916 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MILLER, ROBERT, J. Inventor name: CALIAS, PERICLES |
|
17Q | First examination report despatched |
Effective date: 20070301 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: CALIAS, PERICLES Inventor name: MILLER, ROBERT, J. |
|
APBK | Appeal reference recorded |
Free format text: ORIGINAL CODE: EPIDOSNREFNE |
|
APBN | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2E |
|
APBR | Date of receipt of statement of grounds of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA3E |
|
APAF | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNE |
|
APAF | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
APBT | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9E |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20141009 |